Antibody specialist Nona Biosciences has entered into a strategic collaboration with Chinese bioconjugation company GeneQuantum Healthcare.
Nona is a wholly-owned subsidiary of Hong Kong-based HBM Holdings (HKEX: 02142), a global company providing biotech services from target validation and antibody discovery through to pre-clinical research.
The deal will see the firms working together on early-stage discovery work, using Suzhou-headquartered GeneQuantum's iLDC (intelligent ligase-dependent conjugation) and iGDC (intelligent glycotransferase-dependent conjugation) platforms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze